Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$1.09
EPS est.
$1.41
EPS surprise
-22.70%
1-day move
+0.21%
Masimo Corporation reported earnings that fell short of expectations, particularly in EPS, which may raise concerns among investors. Despite the earnings miss, the stock saw a slight increase of 0.21%, indicating some resilience or positive sentiment in the market. The lack of guidance and further commentary from management leaves uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.09 | $1.35 | -22.70% |
| Revenue | — | $392M | — |
No transcript is on record, and the analysis is based on numerical results only.
Masimo Corporation is a healthcare technology company that develops innovative non-invasive monitoring solutions. With a market cap of $9 billion, it plays a crucial role in improving patient outcomes through advanced medical devices and technologies.
Last quarter
In the last quarter, Masimo reported an EPS of -$2.80, significantly missing analyst expectations. The stock saw a slight increase of 0.07% the following day, indicating mixed investor sentiment.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
75%
Avg EPS surprise
-28.73%
Avg 1-day reaction
+1.41%
Analysts have set a consensus EPS of $1.35 and revenue of $392 million for this quarter, reflecting cautious optimism after a disappointing previous quarter.
Bull case
If Masimo can meet or exceed the EPS estimate, it may signal a recovery in profitability and boost investor confidence.
Bear case
A failure to meet expectations could raise concerns about the company's growth trajectory and operational challenges.
Key metrics to watch
EPS
$1.35Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$392MTotal revenue reflects the company's ability to generate sales and is vital for assessing growth potential.
The print will turn on these.
Q1
Will Masimo achieve an EPS of at least $1.35 this quarter?
Meeting this EPS target is crucial for restoring investor confidence after the significant miss last quarter.
Q2
What are the revenue growth prospects for Masimo's new product lines?
Insights into revenue growth from new products will indicate the company's ability to innovate and capture market share.
Why consensus could be wrong
The consensus may underestimate the impact of recent product innovations, which could drive higher revenue growth than anticipated.
Supporting evidence
The company has a strong track record of beating EPS estimates, with an 88% success rate over the last eight quarters.
Recent trends in healthcare spending may favor innovative companies like Masimo, potentially boosting demand for their products.
Key risk
If revenue growth from new products exceeds expectations, it could significantly alter the market's perception of Masimo's growth potential.
Pre-commit to what would confirm each case.
The market is weighing the potential for recovery against the backdrop of recent disappointing earnings.
Bull confirmed if
Achieving an EPS of $1.35 or better would confirm the bull case and indicate a strong recovery.
Bear confirmed if
An EPS below $1.35 would validate concerns about the company's profitability and growth potential.
What the market is pricing for the move.
Implied Move
±2.07%
Historical Avg
±1.8%
The options market is pricing in a modest move, suggesting that investors anticipate some volatility around the earnings announcement.
Options are pricing ±0.6% while MASI has averaged ±1.8% over the last 8 prints — setup is pricing cheap.
30d HV
3.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Masimo beats expectations, history suggests the stock could rise by about 1.36%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns indicating a potential drop of around 0.07%.
The lines on the call that would change the story.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%